Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07038343 · ClinicalTrials.gov registry record · Phase 1
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
A Phase 1 study of Metastatic Solid Tumors and Solid Tumor Cancer, sponsored by Avenzo Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 430
- Enrollment target
- 16
- Study locations
NCT07038343 is a Phase 1 study of Metastatic Solid Tumors and Solid Tumor Cancer that is actively recruiting participants, run by Avenzo Therapeutics. The registered enrollment target is 430 participants, above the 185-participant average among 20 other Metastatic Solid Tumors trials with a reported enrollment target (132% higher). The trial reports 16 study locations across 13 states.
The verdict
NCT07038343, a Phase 1 study of Metastatic Solid Tumors and Solid Tumor Cancer, is actively recruiting participants, sponsored by Avenzo Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 430 participants
- Enrollment target
- 16
- Study locations
Study Summary
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy and potentially in combination therapy to patients with locally advanced or metastatic epithelial solid tumors.
Conditions Studied
Interventions
- DRUG AVZO-1418
- DRUG Combination Agent 1
- DRUG Combination Agent 2
Study Locations (16)
Texas
- Avenzo Therapeutics Recruiting Site - Dallas
- Avenzo Therapeutics Recruiting Site - Houston
- Avenzo Therapeutics Recruiting Site - San Antonio
Florida
- Avenzo Therapeutics Recruiting Site - Orlando
- Avenzo Therapeutics Recruiting Site - Sarasota
Arizona
- Avenzo Therapeutics Recruiting Site - Gilbert
California
- Avenzo Therapeutics Recruiting Site - Los Angeles
Colorado
- Avenzo Therapeutics Recruiting Site - Denver
Connecticut
- Avenzo Therapeutics Recruiting Site - New Haven
District of Columbia
- Avenzo Therapeutics Recruiting Site - Washington D.C.
Georgia
- Avenzo Therapeutics Recruiting Site - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2025-06-04 |
| Est. Completion | 2030-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07038343
The ClinicalTrials.gov registry entry for NCT07038343 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 430 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 185-participant average among 20 other Metastatic Solid Tumors trials with a reported enrollment target (132% higher). The listed sponsor is Avenzo Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Metastatic Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which AVZO-1418 is the first listed.
NCT07038343 reports 16 study locations spanning 13 distinct geographic areas - top geographies include Texas, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT07038343 about?
NCT07038343 is a clinical study titled "AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)". This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy and potentially in combination therapy to patients with loca...
What is the current status of trial NCT07038343?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 430 participants. The study started on 2025-06-04. Estimated completion is 2030-12.
What conditions does trial NCT07038343 study?
This clinical trial studies the following conditions: Metastatic Solid Tumors, Solid Tumor Cancer, Locally Advanced, Lung Cancers, Epithelial Tumor.
What interventions are being tested in trial NCT07038343?
The interventions under investigation include: AVZO-1418 (DRUG), Combination Agent 1 (DRUG), Combination Agent 2 (DRUG).
Who is sponsoring clinical trial NCT07038343?
This trial is sponsored by Avenzo Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07038343 being conducted?
This trial has 16 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
SLV-324 Treatment of Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
RECRUITING · Phase 1
-
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.